Chronic Lymphocytic Leukemia Electronic Patient Reported Outcomes Study
NCT03231579 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 85
Last updated 2019-08-28
Summary
This multi-site study will enroll approximately 100 CLL patients across 5 cancer institutions. The aim of the project is to ensure hematology care teams that are participating in new value-based reimbursement models have an accurate understanding of the evidence and roles of new therapies for CLL and best practice supportive care protocols to proactively assess, monitor, and manage symptoms to promote successful clinical outcomes. Hematology teams at seven health systems across the U.S. will be given online clinical training on the latest evidence for treatment planning in CLL along with best supportive care practices for patients on novel CLL treatments, prior to using Carevive's patient engagement software. Once training is complete, the Carevive software will be employed in the clinic whereby CLL patients will use the Carevive patient portal to report any symptoms at and in between clinic visits. Patients will be given a user name and password to a web-based portal for 24/7 reporting of symptoms experienced. Patient-reported and clinical data will be processed by the Carevive rules engine technology to generate evidence-based supportive care plans providing patients with direction regarding self-management strategies, care coordination for relevant cancer center services, and direction on when to go to the emergency department (ED) or call their hematologist based on their institution's protocol. For patients who require ongoing and routine monitoring, such supportive care recommendations will be included in supportive care plans generated at the clinic visit. On the visits subsequent to the delivery of the care plan, patients will report on the perceived effectiveness of the intervention (or barriers to non-adherence to the intervention). Patients and clinicians will assess symptom severity at each visit for a 16-week period and both data sets will be stored and analyzed for research purposes.
Conditions
Interventions
- BEHAVIORAL
-
Carevive CPS
This intervention will focus on the use of the Carevive CPS, enabling providers to deliver evidence-based and personalized treatment care plans to their CLL patients on/starting treatment. The Carevive CPS collects electronic patient reported outcomes (ePROs) and clinical data, reported and generated by clinical staff and/or peer-reviewed evidence, and includes patient education, resources, and referrals developed by cancer clinicians and researchers.
Sponsors & Collaborators
-
Carevive Systems, Inc.
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-07-21
- Primary Completion
- 2018-11-01
- Completion
- 2019-03-31
Countries
- United States
Study Locations
More Related Trials
-
Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell Chronic Lymphocytic Leukemia
NCT01649791 ·Status: TERMINATED ·Phase: NA
-
A Study to Assess Change in Functioning and Health Related Quality of Life in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Treatments in Routine Clinical Practice in Spain
NCT06125795 ·Status: ACTIVE_NOT_RECRUITING
-
Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia
NCT02157324 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL)
NCT00751296 ·Status: TERMINATED ·Phase: PHASE2
-
Prospective Collection of Biological Data of Prognostic Relevance in Patients With B-Cell Chronic Lymphocytic Leukemia
NCT00917540 ·Status: UNKNOWN
-
Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL
NCT04215809 ·Status: RECRUITING ·Phase: PHASE1
-
Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLL
NCT01145209 ·Status: COMPLETED ·Phase: PHASE2
-
Study of MDX-1342 in Patients With Chronic Lymphocytic Leukemia (CLL)
NCT00593944 ·Status: COMPLETED ·Phase: PHASE1
-
Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma
NCT07030400 ·Status: RECRUITING
-
the Real World Study of Orelabrutinib in the Treatment of CLL/SLL
NCT05975164 ·Status: UNKNOWN
-
Effects of a Digital Patient Platform (CMyLife) for Patients With Chronic Myeloid Leukemia (CML) on Information Provision, Patient Empowerment, Medication Compliance, Guideline Adherence and Quality of Life
NCT04595955 ·Status: COMPLETED ·Phase: NA
-
Symptom Burden in Chronic Myeloid Leukemia (CML)
NCT01046305 ·Status: UNKNOWN
-
French Observational Study of Patients With Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma in Real-World Settings
NCT05590702 ·Status: ACTIVE_NOT_RECRUITING
-
Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL
NCT04155710 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluation of ClearLLab Leukemia and Lymphoma Panels
NCT03413644 ·Status: COMPLETED
-
Clinical Study of Orelabrutinib Combined With BG Regimen First-line Treatment of CLL/SLL
NCT05918276 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Dasatinib Combination for Chronic Lymphocytic Leukemia(CLL) With Refractory Disease
NCT01051115 ·Status: UNKNOWN ·Phase: PHASE2
-
Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FL
NCT04342117 ·Status: TERMINATED
-
Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.
NCT02315768 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Studying Biomarkers in Cell Samples From Patients With Acute Myeloid Leukemia
NCT01057199 ·Status: COMPLETED
-
PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT01500733 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Lenalidomide in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT00439231 ·Status: COMPLETED ·Phase: PHASE2
-
Determining Clinical Study Experiences of Chronic Lymphocytic Leukemia Patients
NCT05899543 ·Status: NOT_YET_RECRUITING
-
C-X-C Chemokine Receptor 4 in Chronic Lymphocytic Leukemia
NCT03150849 ·Status: UNKNOWN
-
Lenalidomide in Chronic Lymphocytic Leukemia (CLL) Patients With Residual Disease
NCT00632359 ·Status: COMPLETED ·Phase: PHASE2